Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy

During the past decade, proof of the principle that peptide receptors can be used successfully for in vivo targeting of human cancers has been provided. The molecular basis for targeting rests on the in vitro observation that peptide receptors can be expressed in large quantities in certain tumors.

Read More

Jim’s Prostate Journey

To all the friends I haven’t met yet who have discovered their PSA is rising.

Your blood test will include your PSA, prostate specific antigen, which is the gold standard for monitoring the health of the prostate gland. After a friend’s Doctor missed his annual rise in PSA I began watching my own keeping copies of annual and semiannual blood tests. Good news, my PSA was in the 2.4 range for many years well within acceptable levels.

Read More

Development of a voided urine assay for detecting prostate cancer non-invasively: a pilot study


These preliminary data are highly encouraging and warrant further evaluation of the assay to serve as a simple and reliable tool to detect prostate cancer non- invasively.

Read More

Precision-based medicine improves outcomes and drives down costs

As health care costs continue to skyrocket, oncologists are looking for ways to effectively treat their patients without the added burden of enormous medical bills.

According to the National Cancer Institute, the U.S. spends approximately $157 billion on cancer care per year. In 2014, spending on oncology medication surpassed $100 billion worldwide. As patients are footing the bill for more of their medical expenses, they are increasingly aware of these escalating costs. According to a survey by Premier, Inc., 56 percent of C-suite hospital executives plan to invest more in cost-cutting avenues to meet patient demand.

Read More

NVLS: Emerging Technology Means Shift Needed Towards Diagnostic Testing Markets

Cancer diagnostics technology continues to evolve, with emerging science based in precision medicine beginning to dominate the industry. Even though global markets are primarily focused on cancer therapeutics, new trends in the development of cancer diagnostic technology will shape the future of these markets.

Read More

Emerging Technologies for Precision-Based Cancer Diagnostics

Future innovations feature diagnostic and treatment methods that detect and target cancer.

The monetary costs of cancer are well over $87 billion in the United States, and even more costly is the loss of life, which is anticipated to be 600,920 Americans this year. Out of all deaths in the United States, 25 percent of them are due to some form of cancer. When focusing on breast cancer alone, it is estimated that there will be a quarter of a million new cases diagnosed this year and 40,450 women will die. Financially speaking, the yearly cost of over-diagnosis and false-positive cancer screenings of women age 40-59 is $4 billion. When it comes to prostate cancer, more than 161,000 new cases are anticipated and approximately 26,730 people are expected to die from it this year.

Read More

Cancer Screening Tool Reduces Costs And Invasiveness

Inaccurate and unnecessary cancer screenings cost $88.7 billion annually.

As mounting pressure is put on the healthcare system to reduce costs while improving outcomes, there is a growing need for increased accuracy and closer vetting of testing done to screen for cancer and other diseases. Inaccurate and unnecessary cancer screenings in the U.S. cost an estimated $88.7 billion a year as physicians perform more screenings than in any other country with advanced healthcare. As cancer rates are anticipated to grow by 57 percent worldwide over the next twenty years, the economic impact of these continued screenings must be addressed.

Read More

Black Men are More Likely to Die of Cancer Than Any Other Ethnic Group

Black men are 65% more likely to be diagnosed with prostate cancer and their risk of dying is 36% higher.2

Paul Crowe, Chairman and Chief Executive Officer at Nuview Life Sciences (NVLS), says ethnic groups predisposed to cancer should follow more intensive screening, not less.

Unfortunately, biopsies today are expensive, invasive and often inaccurate:

33% of men with an initial “negative” result for prostate cancer do have prostate cancer that was missed by the biopsy.

Read More

As the Cost of Cancer Treatment Rises, Patients Pay the Price

Cancer remains a crisis in the U.S. in terms of both prevalence and cost. It is the second leading cause of death in the United States accounting for one out of every four deaths. The amount spent treating cancer is staggering. According to a study published in the journal Cancer, the cost of treatment with a newer cancer medication may reach over $100,000 per year for each patient.

Costs of cancer medication are much higher in the U.S. versus other western nations with a similar GDP. The median monthly price of branded cancer drugs, which are still patent-protected, was $8,700 in the U.S., per a recent study, compared to $2,600 in the U.K. and $2,700 in Australia. Pharmaceutical companies seem to exploit the U.S. free market system, where drugs are priced based on supply and demand, to compensate for the lower prices negotiated by other countries. Thus, while the U.S. accounts for just 5 percent of the world’s population, we are stuck with 50 to 70 percent of the globe’s drug profitability.

As health insurance plans move towards a model where patients pay a larger share of expenses – through deductibles or co-insurance – patients are increasingly responsible for covering enormous medication bills.

Read More

Black Men/Women More Likely to Die of Cancer Than Any Other Ethnicity

EthnicityBlack men and women have the highest and second-highest rate of cancer diagnosis respectively.

Black men and women have the highest and second-highest rate of cancer diagnosis respectively.

Black men and women currently are more likely to die of cancer than any other ethnic group.1

With an estimated nearly 200,000 new cancer cases diagnosed among blacks in 2016 – the most common of which include prostate (31% of all cancers) for men and breast (32% of all cancers) for women – Paul Crowe, Chairman and Chief Executive Officer at Nuview Life Sciences (NVLS), says ethnic groups predisposed to cancer should follow more intensive screening.

Unfortunately, biopsies today are expensive, invasive and often inaccurate:

Read More

As Medical Isotope Shortage Looms, Alternative Emerges

NuView Life Sciences Subsidiary emerges to fill the gap.

As Physics World reports, a U.S. National Academies of Sciences, Engineering and Medicine (NAS) report found the U.S. could be facing severe shortages of the vital medical isotope technetium-99m when the aging NRU nuclear reactor in Chalk River, Canada, stops producing molybdenum-99. Technetium-99m, which is derived from the molybdenum-99 isotope, is widely used for medical imaging.

The report found there was a greater than 50 percent chance of severe shortages of the two isotopes following the shutdown of the Canadian reactor. They cannot be stockpiled, since both isotopes have a very short half-life. The Canadian facility was the only North American source, and while other global sources exist, they too come from other aging reactors prone to unscheduled shutdowns.

Read More

U.S. Spends Estimated $7.9 Billion on Unnecessary Biopsies

Breast and Prostate Cancer Biopsy Procedures are Cause of Massive Spend

Diagnosing and treating malignant cancers can be an invasive and expensive process. The U.S. is currently spending an estimated $7.9 billion annually for unnecessary prostate and breast cancer biopsies stemming from either a suspicious mammogram or an elevated prostate‐specific antigen (PSA), as a result of utilizing decades-old technologies to diagnose these cancers. Although there are currently several new diagnostic methods available1, many of these new methods are not confirmatory but rather predictive; they lack sensitivity or specificity in diagnosing and confirming the nature, invasiveness or localization of the disease state; and most of these tests are post-tissue biopsy.

Tissue biopsies performed after a suspicious mammogram or an elevated PSA observed by the physician are uncomfortable for the patient — and expensive. Furthermore, most tissue biopsies often result in benign results.

Read More

Nuevas tecnologías pueden mejorar el diagnóstico de cáncer de las biopsias

Nuevas tecnologías que no requieren cirugía resultan más precisas para detectar la presencia de cáncer y pueden reducir en miles de millones de dólares los gastos médicos de las tradicionales biopsias, según un informe difundido hoy.

“Nuestro nuevo enfoque provee a los médicos de una confirmación de si el paciente tiene cáncer antes de una biopsia quirúrgica”, explicó a Efe Paul Crowe, presidente y gerente general de NuView Life Sciences, una compañía de biotecnología en Park City, Utah.

Según Crowe, el nuevo procedimiento de diagnóstico de cáncer, conocido como Tomografía por Emisión de Positrones, se basa en análisis in vitro de elementos orgánicos para determinar la presencia de biomarcadores atraídos a células cancerosas.

Read More

US-Australian relationship will improve secure supply of important medical isotope

A Dallas-based company has plans to ensure a steady U.S. supply of the most commonly used medical radiotracer in the US, utilizing an expanded Australian reactor and an innovative supply chain.

The October shutdown of a Canadian reactor left North America without a homegrown source of technetium-99, used in around 80% of gamma camera imaging. While the remaining production facilities across the globe can meet baseline demand in the U.S., the supply chain is fragile with reactors that require frequent maintenance or shutdowns.

However, US Radiopharmaceuticals, a subsidiary of NuView Life Sciences, is planning to create a supply chain with the Australian Nuclear Science and Technology Organization (ANSTO) to create a scalable supply of technetium. The potential supply chain would leverage a $168.8 million investment from the Australian government that will go towards expanded production capacity at the Open Pool Australian Lightwater reactor, an isotope production facility just outside of Sydney.

Read More

Emphasis On Precision Medicine, Moonshot Cancer Initiative Spark Diagnosis Advances

NuView Life Sciences’ liquid biopsy tech is changing the cancer diagnosis industry.

Doctor with tablet pc

There has been great emphasis placed on the role of technology in the diagnosis and treatment of diseases like cancer lately, from the Moonshot Cancer Initiative sponsored by Vice President Joe Biden, to the 21st Century Cures Act recently passed by the House of Representative and slated for vote in the Senate soon. Traditional cancer diagnostic methods including biopsies are labor-intensive, expensive, and invasive. Now, NuView Life Sciences (NVLS) has developed a liquid biopsy technology poised to change the way cancer is diagnosed.

Research has revealed genetic mutations present themselves in precancerous or malignant cells, making the identification of such mutations a key factor in early diagnosis and effective treatment for cancer. However, these genetic mutations can be especially hard to pinpoint within the body, and therefore have not been used as a primary method of diagnosis today. Instead, healthcare relies on a series of imaging tests — x-rays, PET scans, mammograms, and ultrasounds — to identify cancerous masses for treatment. However, imaging scans cannot identify microscopic cancers or be used to classify the cellular composition of a tumor, limiting their success in proactively treating disease.

Read More

How Radiologists are Handling the Nuclear Materials Shortage

“We compensated by lowering our doses slightly… you can maintain the same quality by slightly increasing the time of imaging,” Schraml says. “We were able to continue business as usual, essentially.”

Eventually, the shortage abated, and the hospital resumed its original dosages and dosage times.

Regarding the current shortage reports, “I don’t know how dire things will be,” Schraml says. “I put a lot of reliance on my technologists and my manager. They seem to always come through, so if the shortage isn’t any worse than it was a couple of years ago, then I think we’ll be fine.”

The PET Alternative
Technetium-99 is used between 70,000 and 80,000 times per day in U.S. healthcare, primarily as a cardiac perfusion imaging agent, says Paul Crowe, chairman and chief executive officer at NuView Life Sciences, based in Dallas.

Read More